ESMO 2025: Dual targeted therapy shows promise in previously treated advanced kidney cancer patients
Peer-Reviewed Publication
Updates every hour. Last Updated: 23-Oct-2025 22:11 ET (24-Oct-2025 02:11 GMT/UTC)
Results from a trial led by researchers from The University of Texas MD Anderson Cancer Center showed that a targeted therapy combination improved outcomes for patients with metastatic clear-cell renal carcinoma (ccRCC) – a type of kidney cancer – whose disease progressed following immunotherapy.
Like the surface of the moon, new research published today in Cell finds the existence of craters on the surface of melanoma cells that serve as immune hubs, becoming major sites for tumor killing. These craters could serve as good markers for immunotherapy success.